HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Haplotypes of the estrogen receptor beta gene and breast cancer risk.

Abstract
Exposure to exogenous (oral contraceptives, postmenopausal hormone therapy) and endogenous (number of ovulatory cycles, adiposity) steroid hormones is associated with breast cancer risk. Breast cancer risk associated with these exposures could hypothetically be modified by genes in the steroid hormone synthesis, metabolism and signaling pathways. Estrogen receptors are the first step along the path of signaling cell growth and development upon stimulation with estrogens. The National Cancer Institute Breast and Prostate Cancer Cohort Consortium has systematically selected haplotype tagging SNPs in genes along the steroid hormone synthesis, metabolism and binding pathways, including the estrogen receptor beta (ESR2) gene. Four htSNPs tag the 6 major (>5% frequency) haplotypes of the ESR2 gene. These polymorphisms have been genotyped in 5,789 breast cancer cases and 7,761 controls nested within the American Cancer Society Cancer Prevention Study II, European Prospective Investigation into Cancer and Nutrition, Multiethnic Cohort, Nurses' Health Study and Women's Health Study cohorts. None of the SNPs were independently associated with breast cancer risk. One haplotype of the ESR2 gene was associated with breast cancer risk before correction for multiple testing (OR 1.17, 95% CI 1.07-1.28, p = 0.0007). This haplotype remained associated with breast cancer risk after adjustment for multiple testing using a permutation procedure. There was no statistically significant heterogeneity in SNP or haplotype odds ratios across cohorts. These data suggest that inherited variants in ESR2 (while possibly conferring a small increased risk of breast cancer) are not associated with appreciable (OR > 1.2) changes in breast cancer risk among Caucasian women.
AuthorsBreast and Prostate Cancer Cohort Consortium, David G Cox, Philip Bretsky, Peter Kraft, Paul Pharoah, Demetrius Albanes, David Altshuler, Pilar Amiano, Goran Berglund, Heiner Boeing, Julie Buring, Noel Burtt, Eugenia E Calle, Federico Canzian, Stephen Chanock, Françoise Clavel-Chapelon, Graham A Colditz, Heather Spencer Feigelson, Christopher A Haiman, Susan E Hankinson, Joel Hirschhorn, Brian E Henderson, Robert Hoover, David J Hunter, Rudolf Kaaks, Laurence Kolonel, Loic LeMarchand, Eiliv Lund, Domenico Palli, Petra H M Peeters, Malcolm C Pike, Elio Riboli, Daniel O Stram, Michael Thun, Anne Tjonneland, Ruth C Travis, Dimitrios Trichopoulos, Meredith Yeager
JournalInternational journal of cancer (Int J Cancer) Vol. 122 Issue 2 Pg. 387-92 (Jan 15 2008) ISSN: 1097-0215 [Electronic] United States
PMID17935138 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2007 Wiley-Liss, Inc.
Chemical References
  • Estrogen Receptor beta
Topics
  • Adult
  • Alleles
  • Breast Neoplasms (diagnosis, ethnology, genetics, metabolism)
  • Estrogen Receptor beta (biosynthesis, genetics)
  • Female
  • Gene Expression Regulation, Neoplastic
  • Genetic Predisposition to Disease
  • Genotype
  • Haplotypes
  • Humans
  • Odds Ratio
  • Polymorphism, Genetic
  • Polymorphism, Single Nucleotide
  • Regression Analysis
  • Risk
  • White People

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: